-
2024-518438-94-00
4
2025-10-24
Heart failure
-
2025-520464-17-00
4
2025-10-21
Atherosclerotic Cardiovascular disease
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2025-521377-14-00
4
2025-10-06
Atrial fibrillation
-
2023-508056-19-00
5
2025-10-02
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
-
2024-520386-31-00
5
2025-09-22
Locally Advanced Head & Neck Squamous Cell Carcinoma
-
2024-516982-35-00
5
2025-09-11
Ovarian Cancer
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2023-508875-35-00
5
2025-09-01
Heart condition
-
2024-519331-42-00
5
2025-08-22
pMMR endometrial carcinoma
-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2024-512583-57-00
5
2025-07-30
HER2-positive locally advanced or metastatic gastric or gastroesophage
-
2024-519059-28-00
5
2025-07-17
Chronic Heart Failure
-
2024-516834-36-00
5
2025-07-08
Locally recurrent unresectable or metastatic TNBC with tumors expressi
-
2024-513869-39-00
5
2025-06-27
Obstructive Cardiomyopathy, Hypertrophic
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-519116-14-00
4
2025-05-27
Asthma
-
2023-506327-29-00
5
2025-05-14
Non-Small Cell Lung Cancer
-
2024-516363-92-00
5
2025-04-08
Psychosis Associated with Alzheimer’s Disease
-
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
-
2024-515566-13-00
5
2025-03-19
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2023-509234-19-00
4
2025-03-03
Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-s
-
2024-514281-39-00
5
2025-02-14
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD